Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.11.2016 | review article | Ausgabe 21-22/2016 Open Access

Wiener klinische Wochenschrift 21-22/2016

Neuromuscular electrical stimulation of the thighs in cardiac patients with implantable cardioverter defibrillators

Wiener klinische Wochenschrift > Ausgabe 21-22/2016
Dr. Fadime Cenik, Dr. Dieter Schoberwalter, Dr. Mohammad Keilani, Dr. Bruno Maehr, Univ. Prof. Dr. Michael Wolzt, Dr. Maximilian Marhold, MBA, MSc Univ. Prof. Dr. Richard Crevenna
Wichtige Hinweise
Dr. Fadime Cenik and Dr. Dieter Schoberwalter have contributed equally.



The aim of this systematic review was to update scientific knowledge concerning the safety of neuromuscular electrical stimulation (NMES) to increase exercise capacity and prevent cardiac cachexia in patients with implantable cardioverter defibrillators (ICDs).


A systematic review including the electronic databases PubMed, MEDLINE, and SCOPUS was conducted for the time period from 1966 to March 31, 2016.


Only four articles fulfilled the inclusion criteria (three original articles/safety studies and one case report). The three (safety) studies used NMES to increase muscle strength and/or endurance capacity of the thighs. NMES did not show electromagnetic interference (EMI) with ICD function. EMI was described in a case report of 2 patients with subpectoral ICDs and application of NMES on abdominal muscles.


This review indicates that NMES may be applied in cardiac ICD patients if 1) individual risks (e. g., pacing dependency, acute heart failure, unstable angina, ventricular arrhythmic episode in the last 3 months) are excluded by performing a safety check before starting NMES treatment and 2) “passive” exercise using NMES is performed only for thighs and gluteal muscles in 3) compliant ICD patients (especially for home-based NMES) and 4) the treatment is regularly supervised by a physician and the device is examined after the first use of NMES to exclude EMI. Nevertheless, further studies including larger sample sizes are necessary to exclude any risk when NMES is used in this patient group.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 21-22/2016

Wiener klinische Wochenschrift 21-22/2016 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien